Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor
AE Foster, G Dotti, A Lu, M Khalil… - Journal of …, 2008 - journals.lww.com
Transforming growth factor (TGF)-β is produced in most human tumors and markedly inhibits
tumor antigen-specific cellular immunity, representing a major obstacle to the success of
tumor immunotherapy. TGF-β is produced in Epstein-Barr virus (EBV)-positive Hodgkin
disease and non-Hodgkin lymphoma both by the tumor cells and by infiltrating T-regulatory
cells and may contribute the escape of these tumors from infused EBV-specific T cells. To
determine whether tumor antigen-specific cytotoxic T lymphocytes (CTLs) can be shielded …
tumor antigen-specific cellular immunity, representing a major obstacle to the success of
tumor immunotherapy. TGF-β is produced in Epstein-Barr virus (EBV)-positive Hodgkin
disease and non-Hodgkin lymphoma both by the tumor cells and by infiltrating T-regulatory
cells and may contribute the escape of these tumors from infused EBV-specific T cells. To
determine whether tumor antigen-specific cytotoxic T lymphocytes (CTLs) can be shielded …